MIV-210

MIV-210 is an oral small‑molecule nucleoside analogue prodrug, chemically known as lagociclovir valactate, that is converted in vivo to 3′‑fluoro‑2′,3′‑dideoxyguanosine (2′,3′‑dideoxy‑3′‑fluoroguanosine), a guanosine analogue with potent inhibitory activity against hepatitis B virus (HBV) and human immunodeficiency virus (HIV). It is efficiently absorbed orally and phosphorylated intracellularly to its active triphosphate, which acts as a DNA chain terminator at the viral polymerase/reverse transcriptase, thereby blocking HBV DNA synthesis and HIV reverse transcription, including in strains resistant to lamivudine, adefovir, entecavir, and multi‑nucleoside‑resistant HIV variants.[1][2][5][9][11] Originally developed by Medivir, with prior licensing collaborations involving GlaxoSmithKline and Daewoong Pharmaceutical, MIV-210 advanced into phase 2 clinical development for chronic HBV infection and treatment‑experienced HIV‑1 infection but was later discontinued as a commercial development project.[2][8][11][14]

Other names

lagociclovir valactatelagociclovir